MOLN Molecular Partners AG ADRs
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland. This is an ADR of a company whose stock trades outside of the U.S. as the symbol SE:MOLN.
$5.94 0.00 (0.00%)
As of 03/24/2023 00:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Switzerland
Country of incorporation:
IPO date: 11/05/2014
Outstanding shares: 36,056,916
Average volume: 2,794
Market cap: $215,980,927
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol: BRJLB32
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%